Primitive neuroectodermal tumors of the abdominal wall and vulva in children: Report of two cases and review of the literature

Qiong-Qian Xu, Wen-Wen Xing, Gang Chen, Yi-Wu Dang, Yi-Ge Luo, Peng Chen, Song-Wu Liang, Jia-Bo Chen

ORCID number: Qiong-Qian Xu (0000-0003-0924-2658); Wen-Wen Xing (0000-0001-8963-0253); Gang Chen (0000-0002-4864-1451); Yi-Wu Dang (0000-0002-7793-1239); Yi-Ge Luo (0000-0002-292-4482); Peng Chen (0000-0001-5893-8120); Song-Wu Liang (0000-0002-5664-8776); Jia-Bo Chen (0000-0003-1757-3481).

Author contributions: Chen G, Dang YW, Luo YG, and Chen JB designed the research, supervised all experiments and corrected the manuscript; Xu QQ, Xing WW, Chen P, and Liang SW collected the clinical information, summarized literature, and performed histologic examination and immunohistochemistry; and Xu QQ wrote first version of the paper.

Supported by the Guangxi Natural Science Foundation Project, No. 2014GXXSFAA118202.

Informed consent statement: The patients provided informed consent for publication of the case.

Conflict-of-interest statement: The authors of this manuscript have no conflicts of interest to disclose.

CARE Checklist (2016) statement: The manuscript was revised according to the CARE checklist.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to

Abstract

BACKGROUND

Primitive neuroectodermal tumors are rare, highly malignant small round cell tumors belonging to the Ewing sarcoma family. The purpose of this article is to present clinical manifestation, histology, treatment, and prognosis of two primitive neuroectodermal tumors (PNETs) in extremely rare anatomic locations, the abdominal wall and vulva.

CASE SUMMARY

Case 1 was a 66-month-old girl with lesions on the abdominal wall; tumor size was about 3.4 cm × 6.1 cm × 2 cm. The patient underwent radical resection of the tumor. After the operation, an alternating vincristine, doxorubicin, and cyclophosphamide/ifosfamide and etoposide (IE) regimen was given for eight cycles, and the patient survived for 66 mo without progression. Case 2 was a 40-month-old girl, with a vulvar lesion; tumor size was about 3.3 cm × 5 cm × 2.5 cm. The tumor was partially resected by surgery. The family left treatment after two cycles of vincristine, pirarubicin, and cyclophosphamide/IE chemotherapy, and the patient died at home six months after surgery.

CONCLUSION

PNET is a rare, fast-growing, highly malignant tumor that requires histologic and molecular analyses for exact diagnosis, and multimodal treatment is required to achieve a good prognosis.

Key words: Primitive neuroectodermal tumor; Therapy; Prognosis; Case report

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Primitive neuroectodermal tumors (PNETs) are rare undifferentiated tumors with similar biological characteristics. They belong to the Ewing sarcoma family, accounting for 4% to 17% of all pediatric soft tissue tumors. PNETs usually occur in children and young adults under 25 years of age. We retrospectively analyzed two PNET cases at the First Affiliated Hospital of Guangxi Medical University from May 2012 to June 2014. Both patients were female with an age of onset at 66 and 40 mo. Both patients were provided inpatient visits, outpatient medical records, and telephone follow-ups for more than one year. In this report, we describe in detail the clinical manifestations, treatment protocols, pathological findings, and patient prognoses. This report provides an in-depth analysis of two cases of PNET at rare sites.

INTRODUCTION

Primitive neuroectodermal tumors (PNET) are rare undifferentiated tumors with similar biological characteristics. They belong to the Ewing sarcoma family, accounting for 4% to 17% of all pediatric soft tissue tumors. Ewing sarcoma PNETs (ES/PNETs) usually occur in children and young adults under 25 years of age[1-3]. There are two main types according to cell location and origin: Central PNET (cPNET) and peripheral PNET (pPNET). The cPNETs are derived from the neural tube and mainly involve the brain and spinal cord, while the pPNETs are derived from the neural crest and occur outside the central nervous system, and often involve the sympathetic nervous system or soft tissue and bone[4]. We report on two patients presenting with PNETs located in the abdominal wall and vulva. As far as we know, only 13 cases of abdominal wall PNET and 37 cases of vulvar PNET have been reported.

We retrospectively analyzed these two PNET cases at the First Affiliated Hospital of Guangxi Medical University from May 2012 to June 2014. Both patients were female with an age of onset at 66 and 40 months. Both patients were provided inpatient visits, outpatient medical records, and telephone follow-ups for more than one year (Table 1). In this case report, we describe in detail the clinical manifestations, treatment protocols, pathological findings, and patient prognoses. This report provides an in-depth analysis of two cases of PNET at rare sites.

CASE PRESENTATION

Chief complaints
Case 1: A 66-month-old girl with no traumatic medical history presented with reported abdominal pain two months ago.

Case 2: A 40-month-old girl presented with a mass (the size of a broad bean) at the external vaginal orifice, accompanied by intermittent hemorrhage.

History of present illness
Case 1: Two months ago, the girl began to present with reported abdominal pain without any obvious causes.

Case 2: Eight months ago, the girl began to present with a mass (the size of a broad bean) at the external vaginal orifice, which was grown up and accompanied by intermittent hemorrhage.

History of past illness
Case 1: The patient has no special past history.

Case 2: The patient was diagnosed with pPNET via pathological biopsy at another hospital. But she did not receive surgical interventions.
Table 1  Follow-up data of two cases of primitive neuroectodermal tumor patients

| Case | Age (mo) | Position      | Size (cm)       | Therapy         | Survival (mo) | Outcome |
|------|----------|---------------|-----------------|-----------------|---------------|---------|
| 1    | 66       | Abdominal wall | 3.4 × 6.1 × 2.0 | S + Ch (VDC/IE) | 66+           | Survival|
| 2    | 40       | Vulva         | 3.3 × 5.0 × 2.5 | S + Ch (VAC/IE) | 14            | Death   |

F: Female; S: Surgery; Ch: Chemotherapy.

Personal and family history
Both of the two patients had no significant personal or family history.

Physical examination upon admission
Case 1: Clinical examination revealed a large mass in her right abdomen approximately 5 cm × 5 cm.

Case 2: Physical examination revealed a 3 cm × 3 cm × 1 cm, red, irregular, soft mass located on the external vaginal orifice; no other symptoms were noted.

Laboratory examinations
Case 1: The patient had no significant laboratory test result.

Case 2: Laboratory examination revealed a hemoglobin level of 118 g/L (normal range: 120-160 g/L), blood platelet count of 422 × 10^9/L (normal range: 125 × 10^9/L to 355 × 10^9/L), neutrophil percentage of 20.9% (normal range: 40%-75%), neuron specific enolase level of 61.96 ng/mL (normal range: 0.00-23.00), international normalized ratio of 0.75 (normal range: 0.80-1.40), and prothrombin time of 8.90 s (normal range: 9.00-15.00 s).

Imaging examinations
Case 1: Computed tomography (CT) showed a fusiform soft tissue density between the abdominis obliquus internus musculus and the abdominal transverse muscle in the right inferior abdominal, with a density measuring about 3.4 cm × 6.1 cm with irregular patchy calcification, evenly enhanced in the middle of the right lower abdominal wall (Figure 1). No evidence of metastatic disease was uncovered after a complete examination.

Case 2: Pelvic CT showed an irregular soft tissue density in the patient’s vagina with some protruding lesions ranging over an area of about 3.3 cm × 5 cm × 2.5 cm. A boundary was not clear, nor was the inner wall of the normal vagina, and the enhancement scanning showed that the lesion was enhanced (Figure 2). No evidence of distant metastases was revealed upon head, chest, and abdominal CT.

TREATMENT

Case 1
During surgery to remove the mass, a gray-white mass measuring approximately 4 cm × 3 cm × 2 cm was excised from between the abdominis obliquus internus musculus and the abdominal transverse muscle. The mass was tough and unencapsulated, with a basal portion adhered to the abdominal transverse muscle. There was no invasion of the abdominal transverse muscle membrane. Incision of the tumor revealed calcification and a yellow, turbid liquid.

Case 2
During the surgery, a mass protruding into the vulva about 5 cm × 3 cm × 3 cm in size was visualized, presenting as red, irregular, soft tissue, leading inward to the vagina but clearly separated from the cervix with no cervical invasion. The tumor filled the vaginal orifice, invaded the hymen and urethral orifice, and covered the external urethral orifice. Partial resection was conducted due to the many invasion sites of tumor and the difficulty of complete resection. The operation was completed without complication.
Figure 1  Computed tomography evaluation of Case 1. A: Axial computed tomography image showing a fusiform soft tissue density between the abdominis obliquus internus musculus and the abdominal transverse muscle in the right inferior abdomen; the middle of the mass has irregular patchy calcification; B: Enhanced image showing uniform enhancement of the mass; C and D: The mass involving the musculus transversus abdominis.

**FINAL DIAGNOSIS**

**Case 1**
Histologic examination revealed small round cells with a high nuclear cytoplasmic ratio. Immunohistochemistry showed that the tumor cells were positive for CD99 and Synaptophysin (Syn), and negative for CK, LCA, chromogranin A (CgA), vimentin, CD3, CD20, and CD56 (Figure 3). EWSR1 gene rearrangement was positively confirmed by fluorescent in situ hybridization (FISH) analysis (Figure 4). The patient was thereby diagnosed with pPNET.

**Case 2**
Pathological examination demonstrated round and oval tumor cells in the shape of flakes or beams; cells were abnormal, and mitosis was apparent. On immunohistochemical analysis, the tumor cells were positive for CD99 and vimentin and negative for desmin, CgA, Syn, CD56, NSE, CK, LCA, myogenin, and actin. FISH analysis revealed heterotopic changes in the EWSR1 gene (Figure 5). The diagnosis was pPNET. As the patient's sections were loaned out, we are unable to show the pathology images.

**OUTCOME AND FOLLOW-UP**

**Case 1**
One week after the operation, the patient began treatment with an alternating VDC/IE regimen for eight cycles of chemotherapy. VDC was provided as vincristine (1.5 mg/m²), doxorubicin (37.5 mg/m²), and cyclophosphamide (1.2 g/m²); IE was ifosfamide (1.0 g days 1, 2, 3, 4, and 5) and etoposide (50 mg days 1, 2, 3, 4, and 5). The patient was followed for 66 mo with no relapse or metastatic disease, and currently attends school and functions normally. No treatments followed the eight cycles of chemotherapy.

**Case 2**
The patient received chemotherapy via an alternating VAC/IE regimen three weeks after surgery, as follows: VAC was vincristine (1 mg on day 1), pirarubicin (40 mg on
Figure 2  Computed tomography evaluation of Case 2. A: Axial computed tomography image showing an irregular soft tissue density in the vagina; B: Enhanced image showing non-uniform lesion enhancement; C: Sagittal image showing partial lesion protruding into the vagina.

day 1), and cyclophosphamide (700 mg on day 1); IE was ifosfamide (1.0 g on days 1, 2, 3, 4, and 5) and etoposide (50 mg on days 1, 2, 3, 4, and 5). The patient left treatment after two cycles of chemotherapy and died at home 14 months after diagnosis, approximately six months after surgery. Cause of death was spread of the tumor throughout the body.

DISCUSSION

PNETs originate from the neuroectoderm and are highly malignant tumors with small round cells, first elucidated by Hart and Earle\(^5\) in 1973. In 2013, the WHO pathological classification system updated and removed any differences between PNET and Ewing sarcoma because they demonstrate the same biological characteristics, reclassifying PNET as a member of Ewing sarcoma tumor family\(^6\). Campbell et al\(^7\) compared the epidemiology, clinical features, and outcomes of patients with 3575 reported cases of Ewing sarcoma or PNET over a 40-year period, and proved that the classification by WHO was correct. PNET is known to be a rare disease that rarely occurs in the skin or subcutaneous tissue\(^8\). We reviewed the literature published over an extended period, and found only 13 cases of PNET in the abdominal wall (Table 2) with an average patient age of 27.5 years and maximum age of 65 years, with the youngest being 2 years. The abdominal wall PNET that we examined in this study is the second youngest of all such patients. Only 37 cases of PNET in the vulva were uncovered (Table 3) with an average age of 24.4 years and a maximum age of 65 years. The patient with vulvar PNET examined for this study was only 40 months of age and is the youngest case of vulvar PNET presently reported.

The mechanisms that underlie PNETs are unclear. Roncati et al\(^9\) found a biological accumulation of copper, chromium, aluminum, and bismuth in an abdominal wall PNET patient who had been applying abdominal skin cream for a long period; interestingly, tests revealed that the cream contained aluminum and bismuth, suggesting that these metals were acting as intracellular carcinogens. The high magnetic resistance of bismuth might have interfered with cell electromagnetic equilibrium, and particularly impacted the electromagnetic balance found in neurons containing ES/PNET cells\(^10\). It is worth considering whether heavy metals such as aluminum and bismuth cause the formation of the PNET.

PNET differential diagnosis mainly involves the exclusion of other similar round blue cell tumors, as PNETs and those tumors have some of the same morphological characteristics, which can easily lead to misdiagnosis. Immunohistochemical, reverse transcription-polymerase chain reaction (RT-PCR), and fluorescence in situ hybridization (FISH) analyses are necessary for accurate diagnosis. CD99 and vimentin are the most commonly used immunomarkers in the diagnosis of PNET. Both of our cases were CD99-positive, and although Case 1 was negative for vimentin,
we did show the translocation of the \textit{EWSR1} gene in tumor cells via FISH analysis, confirming the PNET diagnosis. Because both patients’ FISH analyses showed \textit{EWSR1} gene rearrangement, there was no need to test them by RT-PCR. In recent years, scientists have found high expression levels of cyclin D1 in PNET. A study comparing the expression patterns of cyclin D1 in ES/PNET and rhabdomyosarcoma demonstrated that all PNET patients showed a strong, diffuse, nuclear immune response to cyclin D1, while no expression of cyclin D1 was detected in any patients with rhabdomyosarcoma. Cyclin D1 is another highly sensitive immunological marker for the diagnosis of ES/PNET alongside CD99 and FLI-1 markers, although it is not recommended as an independent diagnostic marker thereof\cite{10}.

A main characteristic of PNET\cite{11} is the detection of t (11; 22) (q24; q12) translocation, wherein an EWS-FLI-1 fusion gene is formed. In recent years, scientists have discovered other genetic changes in PNETs. Some researchers found histological and immunohistochemical tumor features consistent with those of PNET in a 15-year-old boy, but no EWSR1 rearrangement was found by FISH and RT-PCR molecular studies. Instead, a translocation of the long arms of chromosomes 18 and 19 was uncovered, resulting in a chromosome t (18; 19) (q23; q13.2) transposition. In addition, some researchers discovered that another translocation in chromosome t (4; 22) (q31n; q12) led to \textit{EWSR1-SMARCA5} gene fusion in patients with PNET.

Because PNET is rare and little research has been performed on it, there is not enough epidemiological and evidence-based medical evidence to derive treatment standards. At present, the main chemotherapeutic drugs used in PNET are vincristine (V), doxorubicin (D), cyclophosphamide (C), actinomycin-D (A), ifosfamide (I), and etoposide (E); our methods of treatment are based on these drugs. Regimens of VAC/IE or VDC/IE are commonly used in chemotherapy, but their chemotherapeutic effects are not always satisfactory. Takigami \textit{et al}.\cite{12} reported on a lung PNET case that had been treated with VDC/IE chemotherapy for 5 mo before surgery; after the tumor was resected, it recurred 1.5 mo later. In this case, adriamycin was replaced with actinomycin-D due to a cumulative dose of doxorubicin near 500 mg/m$^2$. Unfortunately, the tumor grew bigger, and the patient began taking pazopanib (800 mg/d); the tumor shrank four weeks later, and the patient survived for five months, eventually dying due to disease spread. When standard treatment fails, pazopanib can be another effective option. A randomized study of 120 cases of metastatic bone Ewing sarcoma and PNET in the Children’s Cancer Group and the Pediatric Oncology Group in the United States showed that adding ifosfamide and etoposide to standard therapy does not improve outcomes for patients with bone.
Figure 4 Fluorescent in situ hybridization in Case 1. The 5'-terminus of the EWSR1 gene was labeled with red dye, and the 3'-terminus labeled with green dye. Results showed that the red and green signals were isolated from tumor cells, suggesting translocation of the EWSR1 gene (DAPI, 1000×).

Ewing sarcoma or PNET with metastases at diagnosis\(^{[13]}\), although the addition of ifosfamide and etoposide to standard therapy can improve the prognosis of patients with no metastatic disease at the time of diagnosis\(^{[14]}\). The survival time of Ewing sarcoma patients was determined by whether the tumor had metastasized or not; a five-year survival rate was 33% in the case of tumor metastasis and 70% in those without metastasis. Extraosseous origin was an adverse prognostic factor for Ewing sarcoma\(^{[15-17]}\). A retrospective study of 975 patients with Ewing sarcoma in the European Intergroup Cooperative Ewing Sarcoma Study Group indicated that the presence of metastasis at diagnosis, exceptionally large tumors (volume ≥ 200 mL or largest diameter ≥ 8 cm), primary tumors located in the axial skeleton (especially the pelvis), and a histological response of less than 100% were strongly associated with poor survival in Ewing sarcoma\(^{[13]}\). The two cases we report on here were extraosseous in origin, but neither of them had metastasis at diagnosis, nor were they large tumors located in the axial skeleton. Case 1 completed standardized treatment and survived without progression for 66 mo; we consider that this is a successful treatment. Case 2, however, died 14 mo after diagnosis; extraosseous origin might have been an adverse prognostic factor, but the most likely cause of death was cessation of treatment.

In this paper, two extremely rare cases of PNET presenting a primary location in the abdominal wall and vulva are presented. A limitation of this report is the small number of cases reported on, which is due to the rarity of PNETs. We also only analyzed the specific diagnostic methods, pathological results, treatment plans, and follow-up. As survival analysis of the disease and prognostic indicators were lacking, specific tumor staging and treatment criteria could not be provided. When diagnosing PNET, immunohistochemistry is often not enough to provide us with satisfactory diagnostic information, and follow-up by FISH or RT-PCR can make the diagnosis more persuasive. For the treatment of PNET, we chose mass resection by surgery when conditions permit, followed by alternating VAC/IE or VDC/IE chemotherapy. We are increasing our efforts to collect more case data and improve diagnostic parameters for the treatment of PNET. Despite these limitations, we hope that our case report will help inform future clinical work.
### Table 2  Thirteen reported cases of primitive neuroectodermal tumor in the abdominal wall

| Ref. | Age  | Sex | Size (cm) | Immuno- | Molecular/ | MATOD | Therapy | Follow-up | Relapse | Outcome |
|------|------|-----|-----------|---------|------------|-------|---------|-----------|---------|---------|
| Roncati et al[9], 2015 | 45 yr | M | 1.5 | NSE, CD99 (+) | FISH (+) | NA | NA | NA | NA | NA |
| Riccardi et al[9], 2010 | 15 yr | M | 2.5-3.0 | CD99, NB84a, vimentin (+) | FISH, RT-PCR (-) | No | S + Ch | NA | NA | NA |
| Betal et al[9], 2009 | 61 yr | F | NA | CD99, CD56, cytokeratins, S100 (+) | NA | No | S + Ch (6 cycles of VDC) | NA | No | NA |
| Taylor et al[9], 2000 | 33 mo | M | 3.5 × 3.5 × 2.5 | CD99 (+) | NA | No | S | 10 yr | No | Survival |
| Seena et al[9], 2015 | 21 yr | F | 6 × 4 | CD 99, vimentin (+) | NA | No | S + Ch (VDC) | 6 mo | No | Survival |
| Somers et al[9], 2004 | 16 yr | F | 1.5 | CD99, CD56, S100 (+) | FISH and RT-PCR (-) | No | Before metastasis: S + Ch (6 cycles of VDC); after metastasis: S + RT + CT (1 cycle of IE + CBP) | NA | Yes | Death |
| Savic et al[9], 2017 | 15 yr | M | 3.8 × 2.6 × 3.7 | CD99, vimentin, synaptophysin in (+) | RT-PCR (+) | No | S + Ch (VAC) + RT | 8 m | No | Survival |
| Askri et al[9], 2008 | 35 yr | F | 6.5 × 4 | CD99 (+) | NA | NA | S + Ch (3 cycles of VDC) | NA | NA | NA |
| Gurria et al[9], 2011 | 23 yr | F | 14 × 10 × 7 | CD99, PAS (+) | NA | No | S + RT + Ch (VAC/IE) | 8 mo | No | Survival |
| Aydilsi et al[9], 2009 | 65 yr | M | 5 | CD99 (+) | NA | NA | S + Ch (6 cycles of VDCE) | 1 yr | No | Survival |
| Wang et al[9], 2017 | 21 yr | F | 5 × 4 | CD99, vimentin, NSE (+) | NA | Yes | S + RT + Ch (VAC) | 7 mo | Yes | Death |
| Zhan et al[9], 2012 | 2 yr | F | 5.0 × 3.8 × 5.1 | positive CD99, NSE, K67 (+) | NA | No | S + Ch (CTX + ADM + DDP) | 1 yr | No | Survival |
| Present case, 2019 | 66 mo | F | 3.4 × 6.1 × 2 | CD99, Syn (+) | NA | No | S + Ch (VDC/IE) | 66 mo | No | Survival |

+: Positive; MATOD: Metastatic at the time of diagnosis; S: Surgery; Ch: Chemotherapy; RT: Radiotherapy; NA: Not available; FISH: Fluorescence in situ hybridization; RT-PCR: Reverse transcription-PCR; VAC: Vincristine and actinomycin D, cyclophosphamide; IE: Ifosfamide and etoposide; VDC: Vincristine, doxorubicin, and cyclophosphamide.

### Table 3  Thirty-seven reported cases of primitive neuroectodermal tumor in the vulva

| Ref. | Age  | Size (cm) | Immunohistochemistry | Molecular/ cytogenetic analysis | MATOD | Therapy | Follow-up | Relapse | Outcome |
|------|------|-----------|----------------------|-------------------------------|-------|---------|-----------|---------|---------|
| Present case, 2019 | 40 mo | 3.3 × 5 × 2.5 | Vimentin, CD99 (+) | NA | NA | S + Ch (VAC/IE) | 14 mo | YES | Death |
| Pei et al[9], 2018 | 33 yr | 0.5 × 0.5 | PAS, CD99, vimentin (+) | EWSR1 gene (+) | Yes | S + RT + Ch | 15 mo | NO | Survival |
| Chiang et al[9], 2017 | 65 yr | NA | CD99, NSE, SYN, CD56, S100, FLI-1 (+) | FISH (+) | NA | NA | NA | NA | NA |
| Author(s) et al. | Year | Age | Size | CD99, vimentin, FLI-1 (+) | RT-PCR (+) | FISH (+) | Ch (V/IE/PEI) | Outcome |
|-----------------|------|-----|------|---------------------------|-----------|----------|---------------|---------|
| Kakoti et al.   | 2017 | 16 yr | 15 × 10 | CK, vimentin, CD99, FLI-1 (+) | NA | No | Ch (VDC/IE) | NA | NA | Death |
| Tunitsky-Bitton et al. | 2015 | 15 yr | 5 | CD99 (+) | RT-PCR (+) | NA | Yes | S | 2 wk | NA | Death |
| Huang et al.    | 2015 | 20 yr | 8 × 10 × 10 | CD99, vimentin, NSE (+) | NA | Yes | S | 29 | NO | Survival |
| Bakshi et al.   | 2015 | 10 yr | 12 × 8 | MIC2/CD99, FLI-1 (+) | FISH (+) | NA | S + Ch (VIME 5-cycles) | 18 mo | YES | Survival |
| Narayanan et al. | 2015 | 17 yr | 3 × 2 × 2 | MIC2 (+) | NA | NA | S + RT + Ch (VAC/IE) | 22 mo | YES | Death |
| Matsuda et al.  | 2014 | 60 yr | NA | MIC-2, synaptophysin, NSE, neurofilament antibodies (+) | NA | No | S + RT + Ch (VIME) | 48 mo | YES | Survival |
| Xiao et al.     | 2014 | 20 yr | 3 × 2 × 2 | MIC2 (+) | NA | No | S + RT + Ch (PEI, 4 cycles; PAC, 2 cycles) | 13 mo | YES | Death |
| Che et al.      | 2013 | 37 yr | 5 × 3.5 × 3; 3 × 2.4 × 1.2 | CD99, vimentin, FLI-1 (+) | NA | NA | S + Ch (VAC) | 12 mo | YES | Survival |
| Tang et al.     | 2012 | 17 yr | 5.5 × 5 × 5 | CD99 and FLI-1 (+) | NA | NA | S | NA | NA | LS |
| Tang et al.     | 2012 | 25 yr | 2 × 2 × 2 | CD99 and FLI-1 (+) | NA | NA | S | NA | NA | LS |
| Yang et al.     | 2012 | 20 yr | 20 × 10 × 7 | CD99 and NSE (+) | NA | Yes | Ch | NA | NA | Death |
| Kelling et al.  | 2012 | 18 yr | 1.7 × 0.9 × 1.5 | CD99 and vimentin (+) | RT-PCR (+) | Yes | S + RT + Ch | 3 mo | NA | Survival |
| Anastasiades et al. | 2012 | 28 yr | 3 | CD99 (+) | NA | No | S + RT + Ch | 18 mo | YES | Death |
| Dong et al.     | 2012 | 20 yr | 11 × 7.7 × 6.5 | CD99, NSE, CK (AE1/AE3) and Syn (+) | NA | Yes | S | 3 mo | NA | Death |
| Dong et al.     | 2012 | 12 yr | 3.1 | CD99, NSE, CK (AE1/AE3) and Syn (+) | NA | Yes | NA | 13 mo | NA | Survival |
| Dong et al.     | 2012 | 35 yr | NA | CD99 and NSE (+) | NA | Yes | S + Ch | 20 m | YES | Death |
| Halil et al.    | 2011 | 14 yr | NA | CD99 (+) | NA | NA | S + RT + Ch | 9 mo | YES | Death |
| Boldorini et al. | 2010 | 52 yr | NA | CD99, CK(AE1/AE3) and vimentin (+) | FISH (+) | No | S + RT + Ch(VAC/IE) | 12 mo | NO | Survival |
| Dadhwal et al.  | 2010 | 20 yr | 20 × 15 × 10 | CD99 (+) | NA | Yes | S | 20 d | YES | Death |
| Cetiner et al.  | 2009 | 23 yr | 4 × 4 | CD99 and vimentin (+) | RT-PCR (+) | Yes | S + R + Ch (VDC/IE) | 7 yr | NO | Survival |
| Cetiner et al.  | 2009 | 29 yr | NA | CD99 and vimentin (+) | RT-PCR (+) | NA | S + Ch | 51 mo | NO | Survival |
| Fong et al.     | 2008 | 17 yr | 0.7 × 0.6 × 0.2; 2.1 × 1.7 × 1.5 | CD99 and FLI-1 (+) | RT-PCR (+) | No | S + Ch (VDC) | 48 mo | NO | Survival |
| McCluggage et al. | 2007 | 19 yr | 4 | CD99 and FLI-1 (+) | RT-PCR and FISH (-) | NA | S + Ch | NA | NA | NA |
| McCluggage et al. | 2007 | 20 yr | 6.5 | CD99 and FLI-1 (+) | FISH (+) | NA | S + Ch | NA | NA | Death |
| McCluggage et al. | 2007 | 40 yr | 3 | CD99, FLI-1 (+) | FISH (+) | NA | S + Ch | 12 mo | NA | Survival |
| Name            | Year | Age | Stage | Histology | Ch | RT | Survival | Follow-up |
|-----------------|------|-----|-------|-----------|----|----|----------|-----------|
| Moodley et al.  | 2005 | 26  | 4 × 5 | NA        | No | Ch + RT | NA | YES | Death |
| Takeshima et al.| 2001 | 45  | 4 (at recurrence) | Neuron specific enolase, vimentin, HBA 71 (+) | NA | No | S | 1 yr (at recurrence) | YES | Survival |
| Lazare et al.   | 2003 | 15  | 20    | CD99 (+)  | RT-PCR (+) | NA | S + Ch | 7 mo | NO | Survival |
| Vang et al.     | 2000 | 28  | 0.9   | CD99 (+)  | RT-PCR (+) | NA | S + Ch | 18 mo | NA | Survival |
| Paredes et al.  | 1995 | 29  | 5     | Vimentin (+) | NA | NA | S + RT + Ch (6 cycles of VAC) | 8 mo | NO | Survival |
| Nirenberg et al.| 1995 | 20  | 12    | PAS (+)   | NA | NA | S + RT + Ch (VA) | 10 mo | YES | Death |
| Scherr et al.   | 1994 | 10  | 6.5 × 5.5 × 2.0 | HBA-71 (+) | NA | No | S | NA | NA | NA |
| Halib et al.    | 1992 | 23  | 1.5   | CK, EMA (+) | NA | NA | NA | NA | NA | NA |

+: Positive; MATOD: Metastatic at the time of diagnosis; S: Surgery; Ch: Chemotherapy; RT: Radiotherapy; NA: Not available; FISH: Fluorescence in situ hybridization; RT-PCR: Reverse transcription-PCR; PEI: Cisplatin, ifosfamide, and etoposide; PAC: Cisplatin, cyclophosphamide, and actinomycin D; VAC: Vincristine, actinomycin D, and cyclophosphamide; IE: Ifosfamide and etoposide; VDC: Vincristine, doxorubicin, and cyclophosphamide; VIDE: Vincristine, ifosfamide, doxorubicin, and etoposide; VIME: Vincristine, ifosfamide, mesna, and etoposide; LS: Loss to follow-up.

Figure 5  Fluorescent in situ hybridization in Case 2. The separation of the red and green signals indicates that the EWSR1 gene is translocated. Red arrows indicate the translocation change of the EWSR1 gene (DAPI, 1000×).

REFERENCES
1. Celli R, Cai G. Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: A Rare and Lethal Entity. Arch Pathol Lab Med 2016; 140: 281-285 [PMID: 26927724 DOI: 10.5858/arpa.2014-0367-RS]
2. Smoll NR. Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs). Cancer 2012; 118: 1313-1322 [PMID: 21837678 DOI: 10.1002/cncr.26387]
3. Windfuhr JP. Primitive neuroectodermal tumor of the head and neck: incidence, diagnosis, and management. Ann Otol Rhinol Laryngol 2004; 113: 533-543 [PMID: 15274413 DOI: 10.1177/000348940411300705]
4. Park JY, Lee S, Kang IJ, Kim HS, Park SY. Primary Ewing’s sarcoma-primitive neuroectodermal tumor of the uterus: a case report and literature review. Gynecol Oncol 2007; 106: 427-432 [PMID: 17572479 DOI: 10.1016/j.ygcanc.2007.04.036]
5. Hart MN, Earle KM. Primitive neuroectodermal tumors of the brain in children. Cancer 1973; 32: 890-897 [PMID: 4751919 DOI: 10.1002/1097-0142(197310)32:4<890::aid-cncr2820320421>3.0.co;2-o]
6. WHO. International Classification of Disease for Oncology (ICD-O), World Health Organization, Geneva, Switzerland, 3rd edition. 2013.
7. Campbell K, Shulman D, Janeway KA, DuBois SG. Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. Sarcoma 2018; 2018: 1712964 [PMID: 30158829 DOI: 10.1155/2018/1712964]
8. Taylor GB, Chan YF. Subcutaneous primitive neuroectodermal tumour in the abdominal wall of a child: long-term survival after local excision. Pathology 2000; 32: 294-298 [PMID: 11186429 DOI: 10.1080/00313021.2000.1161592]
9. Roncati L, Gatti AM, Capitan F, Barbolini G, Maiorana A, Palmieri B. Heavy Metal Bioaccumulation in an Atypical Primitive Neuroectodermal Tumor of the Abdominal Wall. Ultrastruct Pathol 2015; 39: 286-
Xia C, Narayanan G, Kakoti LM, Wang CM, Aydinli B, Askri A, Savić Đ, Đuričić SM, Miličković M, Đokić D, Grujić B, Vukadin M, Samardžija G, Somers GR, Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voûte PA, Gadner H, Craft AW. Prognostic factors in Ewing's tumor of bone: analysis of 973 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18: 3108-3114 [PMID: 10963639 DOI: 10.1200/CO.2000.18.17.3108]

Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, Fröhlich W, Winkelmann W, Zoubek A, Jürgens H. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998; 9: 275-281 [PMID: 9602261 DOI: 10.1093/annonc/9.2.275]

Jiang S, Wang G, Chen J, Dong Y. Comparison of clinical features and outcomes in patients with extraskeletal vs skeletal Ewing sarcoma: an SEER database analysis of 3,178 cases. Cancer Manag Res 2018; 10: 6227-6236 [PMID: 30535869 DOI: 10.2147/CAMAR.S178979]

Riccardi GF, Stein C, de la Roza G, Damron TA. Newly described transcriptional (18;19)(q23;q13.2) in abdominal wall soft-tissue tumor resembling Ewing sarcoma/primitive neuroectodermal tumor. Cancer Genet Cytogenet 2010; 201: 1-5 [PMID: 20533761 DOI: 10.1016/j.cigc.2010.04.012]

Betal D, Shaybi B, Babu R, Jamil K, Sainsbury RJ. Primitive Neuroectodermal Tumour (PNET) in subcutaneous abdominal wall: a case report. Int Semin Surg Oncol 2009; 6: 10 [PMID: 19335918 DOI: 10.1186/1477-7808-6-10]

Soma S, Shetty SK, Bhat S. PNET of the Abdominal Wall: A Rare Presentation. J Clin Diagn Res 2015; 9: XD01-XD02 [PMID: 26436030 DOI: 10.7860/JCDR/2015/14562.6321]

Somers GR, Shago M, Zielenksa M, Chan HS, Ngan BY. Primary subcutaneous primitive neuroectodermal tumor with aggressive behavior and an unusual karyotype: case report. Pediatr Dev Pathol 2004; 7: 538-545 [PMID: 15547779 DOI: 10.1016/j.pdp.2004.02.2046-9]

Saví D, Duričić SM, Milčković M, Đokić D, Grubić M, Vukadin M, Samardžija G. Extraskeletal Ewing sarcoma in the anterior abdominal wall. Sp. Arh Celok Lek 2018; 146: 207-210 [DOI: 10.2298/SARH170323126S]

Aski A, Farhat LB, Ghariani B, Rabeh A, Dalí N, Said W, Hendauai L. Extraskeletal Ewing sarcoma of the abdominal wall. Cancer Imaging 2008; 8: 156-158 [PMID: 18818133 DOI: 10.1012/1470-7330.2008.0023]

Guarria JP, Dasgupta R. Rhabdomyosarcoma and Extraskeletal Ewing Sarcoma. Children (Basel) 2018; 5 [PMID: 30544742 DOI: 10.3390/children5120165]

Aydilini B, Ozturk G, Yildirmal MI, Polat KY, Basoglu M, Gundogdu C, Kantarci M, Algun M. Extraskeletal Ewing's sarcoma in the abdominal wall: a case report. Acta Oncol 2006; 45: 648-648 [PMID: 16760186 DOI: 10.1080/02841860600549987]

Wang CM, Zeng JT, Zhang YL. Primary neuroectodermal tumor of abdominal wall: a case report and related literature review. Chongqing Yi Xue Za Zhi 2017; 46: 2408-2409

Zhan JH, Luo XR, Guan ZW, Hu XL, Bao GQ, Liu Y. A case of primary primitive neuroectodermal tumor in the abdominal wall. Zhonghua Xian e'er Wai Ke Za Zhi 2012; 33: 719-720 [DOI: 10.3760/cma.j.issn.0125-3036.2012.09.023]

Pei Y, Zhang BZ, Xu GC, Xiao JX. A case of vulva with pelvic metastasis of Ewing sarcoma and review of literature. Shunxi Yi Ke Da Xue Xue Bao 2018; 48: 325-327 [DOI: 10.13753/j.issn.1007-6611.2018.03.026]

Chiang S, Snuderl M, Kojtiro-Sanada S, Quei Pi-Surray A, Daya D, Hayashi T, Bosincu L, Ogawa F, Rosenberg AE, Horn LC, Wang L, Jaffray AJ, Oliva E. Primitive Neuroectodermal Tumors of the Female Genital Tract: A Morphologic, Immunohistochemical, and Molecular Study of 19 Cases. Am J Surg Pathol 2017; 41: 761-772 [PMID: 28296680 DOI: 10.1097/PAS.0000000000000831]

Kakoti LM, Sharma JD, Kataki AC, Barmon D. Primary Ewing Sarcoma of Vulva: A Case Report and a Review of Literature. Indian J Gynecol Oncol 2017; 15: [DOI: 10.4103/0970-4444.20170105-7]

Tanihata-Hitosu E, Uy-Kroh MI, Michener C, Tart ME. Primary Ewing Sarcoma Presenting as a Vulvar Mass in an Adolescent: Case Report and Review of Literature. J Pediatr Adolesc Gynecol 2015; 28: e179-e183 [PMID: 26211932 DOI: 10.1016/j.jpag.2015.04.004]

Huang YR, Kang JL, Li GT. Case of cranial Metastasis of primitive Neuroectodermal tumor of vulva. Guangdong Yi Xue 2015; 36: 3096

Rekhi B, Chinnaoswamy G, Vora T, Shah S, Ranagarajan V. Primary Ewing sarcoma of vulva, confirmed with molecular cytogenetic analysis: A rare case report with diagnostic and treatment implications. Indian J Pathol Microbiol 2015; 58: 341-344 [PMID: 26275259 DOI: 10.4103/0377-4929.162869]

Narayanag R, Rajan V, Puthussery J, Kattoor J, Soman LV. Primitive Neuroectodermal Tumor of the Vulva in an Adolescent Girl. World J Oncol 2014; 5: 220-222 [PMID: 24917407 DOI: 10.14780/wjot.219w]

Matsuda M, Ichimura T, Kasai M, Murakami M, Hoshi M, Kawamura N, Sumi T. Primitive neuroectodermal tumor originating in the vulva: A case report. Oncol Lett 2014; 8: 187-189 [PMID: 24909242 DOI: 10.3892/ol.2014.2073]

Xiao C, Zhao J, Guo P, Wang D, Zhao D, Ren T, Yang J, Shen K, Lang J, Xiang Y, Cui Q. Clinical analysis of primary primitive neuroectodermal tumors in the female genital tract. Int J Gynecol Cancer
Xu QQ et al. PNET in children: Two case reports

2014; 24: 404-409 [PMID: 24463642 DOI: 10.1097/GIC.0000000000000082]

Che SM, Cao PL, Chen HW, Liu Z, Meng D. Primary Ewing's sarcoma of vulva: a case report and a review of the literature. J Obstet Gynaecol Res 2013; 39: 746-749 [PMID: 23106919 DOI: 10.1111/j.1447-0756.2012.02019.x]

Tang X, Wang P, He Y, Yang F, Li L, Wang H, Wang QL, Yao XY, Yang X. [Primitive neuroectodermal tumor in female genital tract: a clinicopathologic study]. Zhonghua Bing Li Xue Za Zhi 2012; 42: 729-732 [PMID: 23302331 DOI: 10.3760/cma.j.issn.0529-5807.2012.11.0084]

Yang J, Guo Q, Yang Y, Zhang J, Lang J, Shi H. Primary vulvar Ewing sarcoma/primitive neuroectodermal tumor: a report of one case and review of the literature. J Pediatr Adolesc Gynecol 2012; 25: e93-e97 [PMID: 22840944 DOI: 10.1016/j.jpag.2012.03.005]

Kelling K, Noack F, Algassan C, Kujath P, Bohlmann MK, Hoellen F. Primary metastasized extraskelatal Ewing sarcoma of the vulva: report of a case and review of the literature. Arch Gynecol Obstet 2012; 285: 785-789 [PMID: 21803144 DOI: 10.1007/s00404-011-1301-4]

Anastasiades EN, El Abiad SA, Chouairy CJ. Ewing sarcoma/primitive neuroectodermal tumor (PNET) of the vulva. Case report and review of the literature. J Med Liban 2012; 60: 113-116 [PMID: 22919869]

Dong YJ, Wang WZ, Zhong DR. Clinicopathological features of primary peripheral primitive neuroectodermal tumors of vulva: a report of 3 case. Linchuang Yu Shiyan Binglixiu Zazhi 2012; 28: 98-100 [DOI: 10.3969/j.issn.1001-7399.2012.01.031]

Hall S, Kucuk M, Arvas M, Aydin O, Calay ZZ. Peripheral primitive neuroectodermal tumor (PNET) of the vulva: a case report. Eur J Gynaecol Oncol 2011; 32: 117-118 [PMID: 21446342 DOI: 10.1007/978-1-4471-4214-0_13]

Boldorini R, Riboni F, Cristina S, Allegrini S, Valentini S, Muscarà M, Ruspa G. Primary vulvar Ewing's sarcoma/primitive neuroectodermal tumor in a post-menopausal woman: a case report. Pathol Res Pract 2010; 206: 476-479 [PMID: 19656640 DOI: 10.1016/j.prp.2009.07.006]

Dadhwal V, Bahadur A, Gupta R, Bansal S, Mittal S. Peripheral neuroectodermal tumor of the vulva: a case report. J Low Genit Tract Dis 2010; 14: 59-62 [PMID: 20040838 DOI: 10.1097/LGT.0b013e3181b0f8f3]

Cetiner H, Kir G, Gelmann EP, Ozdemirli M. Primary vulvar Ewing sarcoma/primitive neuroectodermal tumor: a report of 2 cases and review of the literature. Int J Gynecol Cancer 2009; 19: 1131-1136 [PMID: 19820381 DOI: 10.1111/IGC.0013e3181acea33]

Fong YE, López-Terrada D, Zhai QJ. Primary Ewing sarcoma/peripheral primitive neuroectodermal tumor of the vulva. Hum Pathol 2008; 39: 1535-1539 [PMID: 18662675 DOI: 10.1016/j.humpath.2008.01.013]

McChesney WG, Wellard P, Nucci MR, Hirsch M, Dal Cin P, Wells M, Flanagan AM, Fisher C. Ewing family of tumours involving the vulva and vagina: report of a series of four cases. J Clin Pathol 2007; 60: 674-680 [PMID: 17557870 DOI: 10.1111/jp.2006.049931]

Moodyly M, Jordan A. Ewing's sarcoma of the vulva—a case report. Int J Gynecol Cancer 2005; 15: 1177-1178 [PMID: 16343207 DOI: 10.1111/j.1525-1438.2005.00330.x]

Takehisa N, Tabata T, Nishida H, Furuta N, Tsuzuku M, Hirai Y, Hasumi K. Peripheral primitive neuroectodermal tumor of the vulva: report of a case with imprint cytology. Acta Cytol 2001; 45: 1049-1052 [PMID: 11726102 DOI: 10.1159/000032353]

Lazure T, Alsamad IA, Meuric S, Orbach D, Fabre M. [Primary urterine and vulvar Ewing's sarcoma/peripheral neuroectodermal tumors in children: two unusual locations]. Ann Pathol 2001; 21: 263-266 [PMID: 11468565]

Yang R, Taubenberger JK, Mannion CM, Bijwaard K, Malpica A, Ordonez NG, Tavassoli FA, Silver SA. Primary vulvar and vaginal extracellular Ewing's sarcoma/peripheral neuroectodermal tumor: diagnostic confirmation with CD99 immunostaining and reverse transcriptase-polymerase chain reaction. Int J Gynecol Pathol 2000; 19: 103-109 [PMID: 10782405 DOI: 10.1007/978-0-387-2350-0_02]

Paredes E, Duarte A, Couceiro A, Fernandes D, Alves A, Bastos S. [A peripheral neuroectodermal tumor of the vulva]. Acta Med Port 1995; 8: 161-163 [PMID: 7484244]

Nirenberg A, Östör AG, Slavin J, Riley CB, Rome RM. Primary vulvar sarcomas. Int J Gynecol Pathol 1995; 14: 55-62 [PMID: 7883427 DOI: 10.1097/00004347-199501000-00010]

Scherr GR, d'Ablaing G, Ouzounian JG. Peripheral primitive neuroectodermal tumor of the vulva. Gynecol Oncol 1994; 54: 254-258 [PMID: 8063257 DOI: 10.1006/gyo.1994.1204]

Habib K, Finet JF, Plantier F, Spatz A, Sfoggia D, Fitoussi F. [Rare lesion of the vulva]. Arch Anat Cytol Pathol 1992; 40: 158-159 [PMID: 1449264]
